A 63-year-old Japanese woman with a 30-year history of systemic lupus erythematosus developed macrohematuria and massive proteinuria after seroconversion of myeloperoxidase anti-neutrophil cytoplasmic antibodies (MPO-ANCA). A renal biopsy indicated focal proliferative lupus nephritis (class III A/C) with a fibrous crescent formation. Methylprednisolone pulse therapy (500 mg, 3 successive days) was administered because of progressive proteinuria. Steroid therapy did not suppress the progressive proteinuria; therefore, tacrolimus was added as an alternative immunosuppressive therapy, resulting in the improvement of proteinuria and renal impairment. This case report suggests that MPO-ANCA might play a pathogenic role in the exacerbation of immune-complex-type lupus nephritis.
Introduction
Lupus nephritis (LN) is an immune-mediated renal disease. The pattern of glomerulonephritis (GN) in LN is characterized by immune-complex deposition (1) . Antineutrophil cytoplasmic antibodies (ANCA) have been directly implicated in the pathogenesis of 'pauci-type' glomerular injury and are thought to target myeloperoxidase (MPO) or proteinase 3 on the neutrophil cell surface (2) . The classical renal involvement of ANCA-associated microscopic angiitis is characterized by a pauci-immune necrotizing and crescentic GN (3, 4) . However, recent studies have also identified immune-complex deposition in renal biopsies from these patients (5) . The existence of MPO-ANCA in an immune-complex-type GN has not been extensively studied and the pathological and clinical significance are thus unclear. In this case report, we herein present the clinical and pathological characteristics of a patient with LN with seroconversion of MPO-ANCA and with progressive development of proteinuria and renal impairment. Aggressive immunosuppressive therapy, including high-dose steroids and tacrolimus, effectively improved the macrohematuria, proteinuria and renal impairment.
Case Report
A 63-year-old Japanese woman presented with macrohematuria and massive proteinuria. Her past medical history included systemic lupus erythematosus (SLE), and although there was no renal involvement for 30 years, the patient had suffered from autoimmune hepatitis for 7 years. Thirty years prior to this presentation, the patient presented with high fever (>38 ), a butterfly rash, polyarthralgia and cervical lymphadenopathy. Laboratory investigations revealed high titers of 1anti-nuclear antibodies (×640, diffuse) and anti-DNA antibodies [×1,280, process hazard analysis (PHA) method], as well as hypocomplementemia (CH50, 11.1 U/ mL). However, no abnormalities were indicated by a urinalysis. The patient fulfilled 4 out of the 11 American College of Rheumatology Criteria for SLE and she was thus diagnosed to have SLE. She was successfully treated with corticosteroids (prednisolone, 50 mg/day). Her SLE and autoimmune hepatitis were controlled with prednisolone (10 mg/ day), and no hypocomplementemia or elevated levels of anti-double strand (ds)-DNA antibodies or transaminase were detected. A physical examination revealed that her height was 159.5 cm and weight was 47.9 kg. She was afebrile and her blood pressure was 146/94 mmHg. There were no signs of edema of the face or lower extremities. A chest examination revealed no abnormalities and no hepatosplenomegaly was detected. No skin rash, joint swelling or oral ulcers were observed. Laboratory data are shown in Table. The serum creatinine (Cr) level was marginally elevated (1.1 mg/dL). A urinalysis revealed a massive proteinuria (2.1 g/day) and the sediment contained 200-300 red blood cells/ high-power field, as well as red blood cell casts. A serological evaluation revealed the presence of MPO-ANCA at 119 EU/mL (normal level <10 EU/mL). Although the levels of serum complement (C3 80 mg/dL, C4 11 mg/dL) were marginally decreased, no elevation of anti-ds-DNA antibodies was observed.
A percutaneous renal biopsy was performed in the hospital at day 5. Next, methylprednisolone pulse therapy (500 mg/day, 3 successive days) was initiated, followed by moderate doses of prednisolone (50 mg/day); however, her proteinuria remained unchanged. Cyclophosphamide was not administered after taking into consideration her age and the risk of infection, therefore, tacrolimus (2 mg/day) combined with a steroid therapy was administered. Tacrolimus was tapered to 1 mg/day because of elevated trough levels. The serum levels of Cr and proteinuria improved gradually and the patient was discharged from the hospital at day 71. During that time, laboratory results indicated a creatinine level of 0.8 mg/dL, MPO-ANCA 15 EU and an albumin level of 3.4 mg/dL. A urinalysis showed sediment containing 5-10 red blood cells/high-power field without casts, and <1 g/day proteinuria. MPO-ANCA was measured retrospectively using stored sera. MPO-ANCA was not detected 1 year before admission and there were no previous episodes, including viral or bacterial infections, which are known to trigger seroconversion of ANCA. MPO-ANCA titers increased in parallel with the occurrence of macrohematuria (Fig. 1) . Microhematuria was present at the time of seroconversion of MPO-ANCA and proteinuria was detected one month later. The patient had developed no clinical symptoms, such as fatigue, until the occurrence of macrohematuria. (Fig. 2) Of the 22 glomeruli obtained during the biopsy, four displayed crescent formations, including two fibrous and two fibrocellular crescents. Some glomeruli (less than a half of the glomeruli investigated) showed an active endocapillary proliferation that was associated with mesangial proliferation (Fig. 2A) . The fibrous crescent formation and focal infiltration of the mononuclear inflammatory cells were observed in the interstitium surrounding the atrophic dilated tubules (Fig. 2B) . Fibrocellular crescent formation and the thickened capillary walls with a partial double contour pattern (arrow) of the basement membrane were observed (Fig. 2C) . There was no indication of vasculitis in the interlobular artery walls. An immunofluorescence analysis demonstrated fine granular staining in the mesangium and focally in capillary walls with IgG, IgA, C3, and C1q (Fig. 2D) . Electron microscopy showed electron-dense deposits in the mesangium and in the subendothelial region (Fig. 2E) . These findings were consistent with focal proliferative LN (ISN/RPS class III A/C).
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Discussion
We herein presented a case study for focal proliferative LN with seroconversion of MPO-ANCA. Her clinical course was characterized by macrohematuria, massive proteinuria and progressive renal impairment. A renal biopsy revealed a fibrous crescent formation in addition to focal proliferative changes of the mesangium and capillaries. This patient exhibited clinical features of both MPO-ANCA-associated GN and immune-complex-type LN. Additional clinical findings such as macrohematuria and proteinuria were correlated with MPO-ANCA titers, but not with anti-ds-DNA levels. However, we were unable to identify any disease condition that was distinct from immune-complex-mediated LN on the basis of the renal pathological findings. LN is generally regarded as a classic immune-complex GN, although several investigators have suggested that subgroups of LN with segmental necrosis or crescent formation may have a different pathogenesis (6, 7). These reports have raised the possibility that a mechanism may exist which is similar to that observed in pauci-immune necrotizing and crescentic GN in SLE (8) . The current case report supports a pathogenic role for MPO-ANCA in progressive LN, given that macrohematuria and proteinuria developed in parallel with increasing titers of MPO-ANCA, and with no increase in anti-ds-DNA antibodies.
Approximately 20% of all patients with SLE have ANCA-positivity by indirect immunofluorescence, mainly with the P-ANCA pattern (9); however, ANCAseropositivity by an enzyme-linked immunosorbent assay is less frequently observed (10). Nasr et al. suggested a pathogenic role for ANCA in a subgroup of patients with necrotizing and crescentic LN. They reported 10 cases of LN in which necrosis and crescent formation coexisted with endocapillary proliferation or subendothelial-deposit formation (11). All 10 patients had ANCA positivity, suggesting an overlap between LN and ANCA-associated GN, in which aggressive immunosuppressive therapy is warranted (11) . A paucity of immunoglobulin deposits can be used to distinguish ANCA-associated GN from immune-complex GN, such as LN. However, several studies have suggested that glomerular immune-complex deposition and ANCApositivity are not mutually exclusive (12) . In this regard, our patient displayed unique clinical and pathological findings that showed the possible involvement of MPO-ANCA in a subset of immune-complex-mediated LN. Additional basic and clinical studies are needed to determine whether MPO-ANCA plays a modifying role in immune-complex-mediated glomerulopathy in SLE.
The initial induction therapy in the current patient consisted of methylprednisolone pulse therapy for progressive LN. However, her proteinuria failed to regress. Intravenous cyclophosphamide has been used widely for the treatment of patients with diffuse proliferative LN, but adverse effects such as infections have been noted (13) . Recent reports have indicated that tacrolimus, an immunosuppressant agent, was an effective induction therapy for diffuse proliferative LN (14) , therefore we combined tacrolimus with high-dose steroid therapy. As expected, the serum Cr levels and proteinuria both markedly improved following a course of tapering steroid therapy.
In conclusion, the present case study indicated that progressive LN can occur in patients with serologically-inactive SLE under the conditions of MPO-ANCA seroconversion. Our findings suggest that tacrolimus might therefore be a useful immunosuppressant for treating patients with progressive LN with MPO-ANCA.
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